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THE literature presented illustrates that lipopolysacchar-
ide (LPS), from bacterial cell walls, induces tumour
necrosis factor (TNF) synthesis in macrophages. TNF
affects a number of cell types, amongst which are
endothelial cells, within a few hours. Its injection has been
shown to produce all symptoms of the toxic syndrome. In
the present communication the vulnerability of en-
dothelial cells will be stressed. These cells require
carnitine not only for fatty acid oxidation but also for
membrane protection and repair. As endothelial cells lose
carnitine during hypoperfusion, it is speculated that the
supply of carnitine during the early phase of LPS toxicity
in rats might delay or avoid loss of endothelial functions.
Earlier it was observed that hearts from rats, injected 3 h
previously with LPS, showed strongly increased inter-
stitial fluid production compared to hearts from control
rats, even when TNF was present during a 3 h in vitro
perfusion. It showed that LPS in vivo generates
factors other than TNF, such as platelet activating factor
(PAF), that are responsible for the increased capillary
permeability.
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Introduction
The study of the pathophysiol()gy ()f septic shock
has gained momentum since the discovery that
lipopolysaccharide (I,PS) from the cell walls
Gram-negative bacteria, is mainly responsible for
the toxic syndrome. LPS induces the synthesis
turnout necrosis factor (TNF) in macr()phagcs,
which has been isolated from thesc cells. The
structure ()f TNFo has been determined by cDNA
cloning
2 and appeared identical t() that of cachcctin.
TNF causes cachexia and a state of shock. In vitro,
it is cytostatic ()r cytolytic for vari()us tumour cell
lines. It is not cytotoxic to normal cells. TNF
suppresses lipopr()tein lipasc,
4 an enzyme on
macrophages and vascular cndothclium of red
muscle cells and fat cells for the hydrolysis
glyccridcs ()f plasma lipoprotcins. TNF also affects
other activities of endothelial cells, such as
stimulati(m of procoagulant activity, inducti(m
phospholipase A2
6 and inhibition of proteoglycan
synthesis. It enhances adhesion with neutrophils
and is also an angiogenic peptide.
During studies with the Iangendorff heart, it was
observed that IPS acutely stimulates Ca2+ entry in
cardiomy()cytes, judged by the increase of con-
tractility and endogenous lip()lysis. l,ater it was
found,’2 that when IPS was bound to albumin
during pcrfusion of I,angendorff hearts, it was not
able to stimulate contractility or lipolysis, so that in
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vivo, direct effects of I,PS cannot be important for
the toxic syndrome, but only after its induction of
TNF and platelet activating factor (PAF) produc-
tion. That TNF plays a central role in the
pathogenesis of septic shock has been shown by a
14 17 number of groups.
Involvement of Endothelium
From the brief introduction, it is clear that
endothelial cells play an early and decisive role in
the pathophysiology of shock. These cells are very
vulnerable as they are directly exposed to the
circulating blood, and moreover readily suffer from
(imminent) ischaemia as will be discussed below.
The introduction mentioned the findings of
others on adhesion of cells from the blood to
endothelial cells as leucocytes and thrombocytes.
This is accompanied by a rise of intra-endothelial
Ca2+, which stimulates phospholipase A. It results
in arachidonic acid (and lysophospholipid) release
from membrane phospholipids, which allows the
synthesis of various autacoids. ()he of the
endothelial prostaglandins is prostacyclin. This
PGI. only affects local phenomena, such as
inhibition of platelet aggregation. When endothelial
cells are not activated they do not cause platelet
aggregation as they have a nomthrombogenic
surface (a negatively charged glycocalyx containing
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glycoproteins and proteoglycans, enriched with
heparan- and chondroitin sulphates). Upon surface
damage platelets adhere and aggregate. The
anti-aggregatory effects of PGI2 is due to increase
of cAMP in platelets which lowers their in-
tracellular Ca2+ level, which makes the platelet
insensitive to activation for aggregation. After
exposure to TNF (and/or PAF) activation of
cyclooxygenase rapidly takes place.
19 Whereas PGI2
is the most potent anti-aggregative agent, platelets
make an aggregation promoting thromboxan,
TXA2, from arachidonic acid. The ratio TXA2/PGI2
thercfore is an important determinant for aggrega-
ti(m. Endothelium derived relaxing factor (EDRF,
i.e. the free radical N()), increases cGMP in
platelets, which like cAMP decreases its Ca2+ level
and inhibits aggregation. Other endothelial com-
pounds of great interest are endothelins-1, -2 and
-3. They are vasoconstrictors, consisting of 21
amino acids and derived from ’big-endothelin’.
2
As there is no stock of the endothelins in the cells,
it is the converting enzyme that determines their
activity. ET-1 is the strongest vasoconstrictor and
tiT-3 the weakest, but the strongest aggregator of
thrombocytes. Increased levels of endothelins have
been found in septic shock, myocardial infarction
and diabetes. Activation of endothelial cells (e.g. by
thr(mbin) induces the synthesis (f platclet
activating factor (PAF or 1-alkyl-2-acetyl-glyccro-
3-phosphorylcholine).
21 In vitro, it could activate
platelct aggregation. Whether this also holds for in
vivo situations is not certain as it remains within the
cells. PAF, like lysolccithin,
22 affects the cell surfacc.
Vulnerability of Vascular
Endothelium and Loss of Carnitine
liarlier, it was observed that the vascular surface
continuously produces lysophospholipids during
cell free l,angendorff perfusion of control rat
hearts,z This process is stimulated by stress
hormones like glucagon and noradrenaline There-
fore, continuous repair of the phospholipid bilayer
by (activated) fatty acids is required. Hence the
well-known stabilizing effect of palmitoylcarnitine
might partly be due to this process and partly to
the ability (f this amphiphilic compound to affect
membrane fluidity. This stabilization of the cell
surface is even more urgent when tissues are subject
to hypoperfusion when the equilibrium between
synthesis and breakdown is disturbed. Endothelial
cells, in particular, are sensitive to hypoperfusion
as they suffer from their high content of xanthine
dehydrogcnasc, which upon conversion to xanthine
oxidasc may generate (damaging) oxygen free
radicals.24’25
Effect of Carnitine Supply on
Endothelial Functions
Endothelial cells catalyse carnitine dependent
fatty acid oxidation,26 so that they are able to
generate long-chain acyl CoA and acyl carnitine.
That endothelium is most vulnerable to hypoperfu-
sion, as mentioned above, may result in preferential
loss of low molecular components, like carnitine,
from these cells. Indeed, during reperfusion after
ischaemia of Langendorff rat hearts, a loss of
carnitine from a non-myocyte compartment was
observed, probably vascular endothelial cells.
2v It
may explain the restoration of flow regulation by
carnitine addition in imminent ischaemia, as
recently reviewed.2’2 Oxygen free radicals might
be involved in the loss of carnitine from
endothelium, as observed after reperfusion follow-
ing ischaemia.
2v Therefore, carnitine supply may
prevent the loss of flow regulation by endothelium
in imminent ischaemia. Such a situation may be the
early stage of endotoxin shock when capillary flow
in many organs becomes endangered as can be
demonstrated ex vivo, after injection of rats with
LPS. After 3 h the animals showed signs of
dysthermia, lethargy and diarrhoea. Yet their hearts,
tested in vitro during Langendorff perfusion, did not
show contractile failure or lower lipoprotein lipase
activity, indicating intactness of the cardiomyo-
cytes. However, the microcirculation was affected,
judged by an increase of cardiac interstitial fluid
production from 1.08 ___
0.19% (control, n- 6) to
12.6 2.7% (LPS rats, n 6) of the total effluent,
as described previously. The in vitro perfusion of
hearts from control animals for 3 h with TNF
affected neither lipoprotein lipase activity nor
interstitial fluid production. The latter is in
agreement with the conclusions reached by
Langeler et al.
29 based upon studies with an in vitro
model of endothelial monolayers. Therefore, it is
not likely that TNF directly affects increased
permeability, but another product of LPS toxicity,
such as PAF. Preliminary experiments indicated
that 10 nM PAF increased interstitial fluid secretion
during 3 h Langendorff perfusion of hearts from
control rats to 17.3-+-2.9% (n- 3) of the total
effluent. Effects of carnitine and derivatives upon
this phenomenon may be expected since Van
Hinsbergh et al. observed that propionyl carnitine
decreases intracellular Ca2+ levels in thrombin
challenged endothelial cells in culture. PAF has also
been shown to increase intracellular Ca2+ after
specific binding to isolated endothelial cells,’2 so
that carnitine and carnitine derivatives may be
expected to antagonize PAF effects.
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